ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    bcd 057

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis (CALYPSO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02762955
Recruitment Status : Active, not recruiting
First Posted : May 5, 2016
Last Update Posted : March 7, 2018
Sponsor:
Information provided by (Responsible Party):
Biocad

Brief Summary:
CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with moderate to severe plaque psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Biological: BCD-057 Biological: Humira® Phase 3

Detailed Description:

CALYPSO study is the next step of clinical evaluation of adalimumab biosimilar manufactured by joint-stock company (JSC) BIOCAD, Russia.The aim of this study is to establish that BCD-057 is equivalent to Humira® in terms of efficacy, safety and pharmacokinetics when used by the standard regimen in patients with plaque psoriasis.

The study will enroll 344 patients with moderate to severe plaque psoriasis, who will be randomized into 2 groups (1:1 ratio): patients from the first group will receive BCD-057 subcutaneously (SC) at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Then participants of this group will be invited for randomization at week 25 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). Patients will continue to receive 40 mg of BCD-057 on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.

Patients from the second group will receive Humira® subcutaneously (SC) at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. At week 25 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057.They will receive Humira® or BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 344 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: International Multi-center Comparative Randomized Double-blind Clinical Trial of Efficacy and Safety of BCD-057 (Adalimumab Produced by BIOCAD, Russia) and Humira® (Adalimumab Produced by Vetter Pharma-Fertigung Gmbh & Co KG, Germany) in Patients With Moderate to Severe Plaque Psoriasis
Actual Study Start Date : December 2016
Actual Primary Completion Date : December 2017
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Adalimumab

Arm Intervention/treatment
Experimental: BCD-057 group

BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.

BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.

Biological: BCD-057
BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
Other Name: adalimumab

Active Comparator: Humira® group

Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.

BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.

Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa.

Biological: Humira®
Humira is the original adalimumab (produced by F. Hoffman-La Roche)
Other Name: adalimumab




Primary Outcome Measures :
  1. Ratio of patients with PASI75 response after 16 weeks of therapy [ Time Frame: 16 weeks of therapy ]
    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 75% or more (PASI75) after 16 weeks of therapy with adalimumab vs. baseline.


Secondary Outcome Measures :
  1. PASI Improvement (%) after 16, 24, 33 and 55 weeks of therapy with adalimumab. [ Time Frame: 16, 24, 33 and 55 weeks of therapy ]
    Percent improvement in Psoriasis Area Severity Index (PASI) after 16, 24, 33 and 55 weeks of therapy with adalimumab.

  2. Ratio of patients with PASI75 response after 24, 33, 55 weeks of therapy [ Time Frame: 24, 33 and 55 weeks of therapy ]
    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 75% or more (PASI75) after 33, 55 weeks of therapy with adalimumab vs. baseline.

  3. Ratio of patients with PASI50 and PASI90 response after 16, 33, 55 weeks of therapy. [ Time Frame: 16, 24, 33 and 55 weeks of therapy ]
    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 50% or more (PASI50) and Psoriasis Area Severity Index score by 90% or more (PASI90) after 16, 24, 33, 55 weeks of therapy with adalimumab vs. baseline.

  4. Ratio of patients with sPGA response after 16, 33, 55 weeks of therapy [ Time Frame: 16, 24, 33 and 55 weeks of therapy ]
    Ratio of patients who have Physicians Global Assessment (sPGA) score 0 or 1 after 16, 33, 55 weeks of therapy with adalimumab.

  5. BSA Improvement (%) after 16, 24, 33, 55 weeks of therapy [ Time Frame: 16, 24, 33 and 55 weeks of therapy ]
    Percent of body surface area (BSA), affected by psoriasis (measured by physician during physical examination of patient), after 16, 33, 55 weeks of therapy with adalimumab vs. baseline.

  6. Change in SF-36 [ Time Frame: Week 0 to Week 16; Week 16 to Week 55 ]
    Change in Short Form-36 questionnaire (SF-36) from Week 0 to Week 16 and from Week 16 to Week 55.

  7. Change in DQLI [ Time Frame: Week 0 to Week 16; Week 16 to Week 55 ]
    Change in Dermatology Quality of Life Index questionnaire (DLQI) from Week 0 to Week 16 and from Week 16 to Week 55.

  8. Adverse events (AE) severity and frequency related to adalimumab [ Time Frame: 16 and 55 weeks of therapy ]
  9. Overall adverse events (AE) and serious adverse events (SAE) frequency [ Time Frame: 16 and 55 weeks of therapy ]
  10. Frequency of early withdrawal due to AE/SAE [ Time Frame: 16 and 55 weeks of therapy ]
  11. Ratio of patients with binding and neutralizing antibodies to adalimumab [ Time Frame: 55 weeks ]
  12. AUC(0-tau) of adalimumab after multiple adalimumab injections [ Time Frame: 55 weeks ]
    Area under the plasma concentration versus time curve (AUC) 0-tau of adalimumab after multiple adalimumab injections

  13. Cav,ss of adalimumab after multiple adalimumab injections [ Time Frame: 55 weeks ]
    Average blood concentration of adalimumab in steady state conditions (Cav,ss)

  14. Т½ of adalimumab after multiple adalimumab injections [ Time Frame: 55 weeks ]
    Half-life (Т½) of adalimumab after multiple adalimumab injections

  15. Vd of adalimumab after multiple adalimumab injections [ Time Frame: 55 weeks ]
    Volume of distribution (Vd) of adalimumab after multiple adalimumab injections

  16. Cl of adalimumab after multiple adalimumab injections [ Time Frame: 55 weeks ]
    Clearance (Cl) of adalimumab after multiple adalimumab injections



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient had written informed consent.
  • Age between 18 and 75 years.
  • Patient has moderate to severe plaque psoriasis with stable course of the disease for 6 months
  • Patient has had at least 1 course of phototherapy or systemic treatment for psoriasis or are candidates for such treatment in opinion of Investigator.
  • BSA affected by psoriasis ≥ 10%, PASI score ≥ 12, sPGA score ≥ 3.
  • Patient has hemoglobin ≥ 10 g/dl, leucocytes count ≥ 3 000/mcl, thrombocytes count ≥ 100 000/mcl, neutrophil count ≥ 2 000/mcl, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase exceed 2,5 or less times the upper limit of the normal range creatinine less than 176,8 µmol/l, no serologic or virologic markers of hepatitis B virus and hepatitis C virus, negative urine pregnancy test, no signs of tuberculosis (negative tuberculosis skin test or negative quantiferon test. Patients can be included in they have positive tuberculin test, have had Bacteria Calmette-Guerin (BCG) vaccination and have negative Diaskintest or negative quantiferon test. Patients can be included if they have positive tuberculin test, have not been vaccinated with BCG and also patients with positive or uncertain quantiferon test/Diaskintest if they have documented adequate prophylaxis of tuberculosis finished before first adalimumab injection AND have documented absence of contacts with patients who have active tuberculosis AND have no signs of tuberculosis on chest X-Ray that was performed during 3 months before randomization)
  • Patients are able to perform all procedures planed by protocol.
  • Patients are ready for contraception with reliable methods starting 2 weeks before entering the study, and up to 4 weeks after the last dose of study drug.

Exclusion Criteria:

  • Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of investigational product on psoriasis.
  • Previous receipt of adalimumab, history of use of any other biological anti-tumor necrosis factor-alpha therapy. Prior use of two or more biologics for treatment of psoriasis.
  • Previous receipt of monoclonal antibodies if they were cancelled less that in 12 weeks before screening
  • Patient is taking corticosteroids for up to 4 weeks before signing informed consent and during screening, disease-modifying drugs including methotrexate, sulfasalazin and cyclosporin for up to 4 weeks before signing informed consent, leflunomide, cyclophosphamide for up to 6 months before signing informed consent, phototherapy including selective phototherapy and photochemotherapy for up to 4 weeks before signing informed consent, live or attenuated vaccines for up to 8 weeks before signing informed consent.
  • Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid phototherapy.
  • Subject has a planned surgical intervention during the study or had surgical intervention less than 30 days prior to study.
  • Subject has an active infection or history of infections as follows: any active infection for which systemic anti-infectives were used within 28 days prior to signing informed consent; a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to signing informed consent; recurrent or chronic infections or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
  • Subject has known history of human immunodeficiency virus or any other severe immunodeficiency.
  • Hepatitis B surface antigen or Hepatitis B core antigen or Hepatitis C antibody positivity at screening.
  • History of tuberculosis.
  • Positive results of rapid plasma reagin-test for T.pallidum at screening.
  • Active ongoing diseases other than psoriasis that might confound the evaluation of the benefit of treatment of adalimumab or can increase risk of adverse reactions: acute inflammatory diseases or exacerbation of chronic diseases otherwise than psoriasis; stable ischemic heart disease III-IV functional class, unstable angina or history of myocardial infarction less than 1 year before the signing of informed consent; moderate to severe heart failure (New York Heart Association [NYHA] class III/IV; severe resistant arterial hypertension, atopic bronchial asthma, history of angiooedema, moderate to severe respiratory insufficiency, chronic obstructive lung disease 3-4 grade, decompensated diabetes mellitus, systemic autoimmune diseases, active neurologic disorders or their symptoms, other underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
  • Subject has history of malignancy within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma.
  • Subject has a history of hypersensitivity to the active substance or to any of the excipients of adalimumab or BCD-057 or other monoclonal antibodies.
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study.
  • Subject has any mental illness, including severe depressive disorders and / or suicidal thoughts in history, which, in the opinion of the investigator, may create excessive risk to the patient or to influence the patient's ability to follow the protocol.
  • History of drug addiction, alcoholism.
  • Simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation; previous participation in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02762955


Locations
Russian Federation
BIOCAD
Saint Petersburg, Strelna, Russian Federation, 198515
Sponsors and Collaborators
Biocad
Investigators
Study Chair: Roman Ivanov, PhD JCS BIOCAD

Responsible Party: Biocad
ClinicalTrials.gov Identifier: NCT02762955     History of Changes
Other Study ID Numbers: BCD-057-2
First Posted: May 5, 2016    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Biocad:
adalimumab
biosimilar
BCD-057
psoriasis
tumor necrosis factor
monoclonal antibody

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies
Antibodies, Monoclonal
Adalimumab
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents